US 12,295,940 B2
Viral inhibitors, the synthesis thereof, and intermediates thereto
Jeffrey Scott Depue, Windham, NH (US); Suresh Kumar Tipparaju, Arlington, MA (US); Helge Alfred Reisch, Sarasota, FL (US); Datong Tang, Weston, MA (US); and Kishore Ramachandran, Westford, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Jul. 18, 2024, as Appl. No. 18/777,473.
Application 18/777,473 is a continuation of application No. 18/379,047, filed on Oct. 11, 2023.
Claims priority of provisional application 63/415,438, filed on Oct. 12, 2022.
Prior Publication US 2024/0366645 A1, Nov. 7, 2024
Int. Cl. A61K 31/4184 (2006.01); A61K 9/00 (2006.01); A61K 31/7056 (2006.01); C07H 19/052 (2006.01)
CPC A61K 31/4184 (2013.01) [A61K 9/0053 (2013.01); A61K 31/7056 (2013.01); C07H 19/052 (2013.01)] 20 Claims
 
1. A composition of maribavir, Compound 2, and Compound 4, the composition comprising maribavir, Compound 2, and Compound 4, having the following structures:

OG Complex Work Unit Chemistry
wherein Compound 2 is present in an amount of 0.1% w/w or less relative to maribavir and Compound 4 is present in an amount of 0.1% w/w or less relative to maribavir.